Login to Your Account



Apex Bioventures Acquiring Dynogen in $135M Stock Deal

By Catherine Hollingsworth


Thursday, February 7, 2008
Apex Bioventures Acquisition Corp. has signed a definitive merger agreement with privately held Dynogen Pharmaceuticals Inc., in a stock deal valued at more than $140 million, based on Apex's share price of $7.27, sources involved in the negotiations said. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription